Cero Therapeutics Holdings Inc (CERO)

Mar 31, 2025, 8:15 AM EDT - 4 days ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

Mar 27, 2025, 8:15 AM EDT - 8 days ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 19, 2025, 8:15 AM EDT - 16 days ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 13, 2025, 8:15 AM EDT - 22 days ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Mar 6, 2025, 8:15 AM EST - 4 weeks ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Mar 5, 2025, 8:15 AM EST - 4 weeks ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

Feb 6, 2025, 8:15 AM EST - 2 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

Feb 5, 2025, 8:00 PM EST - 2 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Dec 6, 2024, 9:00 AM EST - 4 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

Nov 15, 2024, 8:45 AM EST - 5 months ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 11, 2024, 8:15 AM EST - 5 months ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Oct 21, 2024, 9:00 AM EDT - 5 months ago

CERo Therapeutics, Inc. Provides Corporate Update

Oct 2, 2024, 9:15 AM EDT - 6 months ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Sep 25, 2024, 2:49 PM EDT - 6 months ago

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

Sep 25, 2024, 9:17 AM EDT - 6 months ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Jul 18, 2024, 7:55 AM EDT - 9 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN ONVO

Jun 13, 2024, 8:15 AM EDT - 10 months ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

May 15, 2024, 8:00 AM EDT - 11 months ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

Mar 7, 2024, 7:00 AM EST - 1 year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Feb 14, 2024, 4:48 PM EST - 1 year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Jun 5, 2023, 8:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Dec 6, 2022, 9:18 PM EST - 2 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Oct 31, 2022, 8:00 AM EDT - 2 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders